▲ +22.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $36.20, with a high forecast of $45.00 and a low forecast of $29.00. The average price target represents a 22.38% upside from the last price of $29.58.
The current consensus among 5 polled investment analysts is to buy stock in Taysha Gene Therapies.
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.